The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Comparison of real-world effectiveness of all approved BRAF/MEK inhibitor combinations in BRAF-mutant melanoma patients.
 
Anna Czarnecka
No Relationships to Disclose
 
Piotr Blonski
No Relationships to Disclose
 
Bozena Cybulska-Stopa
Honoraria - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; SERVIER
Speakers' Bureau - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre
Travel, Accommodations, Expenses - MSD; Novartis; Pierre Fabre; SERVIER
 
Wieslaw Bal
No Relationships to Disclose
 
Robert Dziura
No Relationships to Disclose
 
Magdalena Ciazynska
No Relationships to Disclose
 
Krzysztof Ostaszewski
No Relationships to Disclose
 
Katarzyna Krawczak
No Relationships to Disclose
 
Magdalena Wisniewska
No Relationships to Disclose
 
Lukasz Galus
No Relationships to Disclose
 
Monika Dudzisz-Sledz
No Relationships to Disclose
 
Natasza Kempa-Kaminska
No Relationships to Disclose
 
Grazyna Kaminska-Winciorek
No Relationships to Disclose
 
Marta Pabianek
No Relationships to Disclose
 
Pawel Rogala
No Relationships to Disclose
 
Tomasz Kubiatowski
No Relationships to Disclose
 
Marcin Zietek
No Relationships to Disclose
 
Jacek Mackiewicz
No Relationships to Disclose
 
Tomasz Switaj
No Relationships to Disclose
 
Piotr Rutkowski
Honoraria - Bristol-Myers Squibb; Genesis Pharma; Medison; Merck; MSD; Novartis; Pierre Fabre
Consulting or Advisory Role - Amgen; AstraZeneca; Blueprint Medicines; Bristol-Myers Squibb; MSD; Novartis; Philogen; Pierre Fabre
Speakers' Bureau - Genesis Pharma; Medison; Pierre Fabre
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst); Pierre Fabre (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Orphan Europe; Pierre Fabre